These data confirmed the co-expression of PD-L1 and CD47 on several tumor tissues, suggesting dual blockade of PD-1/PD-L1 and CD47/SIRPα signals by 6MW3211 would offer more clinical benefits than single PD-L1 or CD47 blockade. Here, CD47 is linked to neoplasm.